|
|
| (One intermediate revision not shown.) |
| Line 1: |
Line 1: |
| | | | |
| | ==Crystal structure of the FP domain of human F-box protein Fbxo7 (native)== | | ==Crystal structure of the FP domain of human F-box protein Fbxo7 (native)== |
| - | <StructureSection load='4l9c' size='340' side='right' caption='[[4l9c]], [[Resolution|resolution]] 2.10Å' scene=''> | + | <StructureSection load='4l9c' size='340' side='right'caption='[[4l9c]], [[Resolution|resolution]] 2.10Å' scene=''> |
| | == Structural highlights == | | == Structural highlights == |
| - | <table><tr><td colspan='2'>[[4l9c]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4L9C OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4L9C FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[4l9c]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4L9C OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4L9C FirstGlance]. <br> |
| - | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.1Å</td></tr> |
| - | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4l9h|4l9h]]</td></tr> | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr> |
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">FBX7, FBXO7, HUMAN FBXO7 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4l9c FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4l9c OCA], [https://pdbe.org/4l9c PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4l9c RCSB], [https://www.ebi.ac.uk/pdbsum/4l9c PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4l9c ProSAT]</span></td></tr> |
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4l9c FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4l9c OCA], [http://pdbe.org/4l9c PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4l9c RCSB], [http://www.ebi.ac.uk/pdbsum/4l9c PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4l9c ProSAT]</span></td></tr> | + | |
| | </table> | | </table> |
| | == Disease == | | == Disease == |
| - | [[http://www.uniprot.org/uniprot/FBX7_HUMAN FBX7_HUMAN]] Parkinsonian-pyramidal syndrome. The disease is caused by mutations affecting the gene represented in this entry. | + | [https://www.uniprot.org/uniprot/FBX7_HUMAN FBX7_HUMAN] Parkinsonian-pyramidal syndrome. The disease is caused by mutations affecting the gene represented in this entry. |
| | == Function == | | == Function == |
| - | [[http://www.uniprot.org/uniprot/FBX7_HUMAN FBX7_HUMAN]] Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes BIRC2 and DLGAP5.<ref>PMID:15145941</ref> <ref>PMID:16510124</ref> | + | [https://www.uniprot.org/uniprot/FBX7_HUMAN FBX7_HUMAN] Substrate recognition component of a SCF (SKP1-CUL1-F-box protein) E3 ubiquitin-protein ligase complex which mediates the ubiquitination and subsequent proteasomal degradation of target proteins. Recognizes BIRC2 and DLGAP5.<ref>PMID:15145941</ref> <ref>PMID:16510124</ref> |
| - | <div style="background-color:#fffaf0;">
| + | |
| - | == Publication Abstract from PubMed ==
| + | |
| - | The FP (Fbxo7/PI31) domains found in the F-box protein Fbxo7 and the proteasome inhibitor PI31 mediate the homodimerization and heterodimerization of Fbxo7 and PI31. Fbxo7 is the substrate-recognition subunit of the SCF(Fbxo7) (Skp1-Cul1-F-box protein) E3 ubiquitin ligase that catalyzes the ubiquitination of hepatoma up-regulated protein (HURP) and inhibitor of apoptosis protein (IAP). Fbxo7 also interacts with proteins that are not substrates of the ubiquitin proteasome system, such as Cdk6 and PI31. Here, the crystal structure of the Fbxo7 FP domain is reported at 2.0 A resolution. The Fbxo7 FP domain adopts an alpha/beta-fold similar to that of the PI31 FP domain. However, an alpha-helix and three beta-strands in the Fbxo7 FP domain are longer than their counterparts in the PI31 FP domain. The differences in these secondary-structural elements are spatially clustered to define a more structured and extended C-terminal end of the Fbxo7 FP domain. The two FP domains also differ substantially in the length and conformation of the longest connecting loop. More importantly, structural differences between the two FP domains lead to drastically different modes of inter-domain protein-protein interaction. The inter-domain interface of the Fbxo7 FP domain is defined by the alpha-helical surface in one protomer and the beta-sheet surface in the other protomer, whereas for the PI31 domain it is defined by either the alpha-helical surfaces or the beta-sheet surfaces in both protomers. The inter-domain interaction of the Fbxo7 FP domain is much more extensive, featuring a larger contact surface area, better shape complementarity and more hydrophobic and hydrogen-bonding interactions. The Fbxo7 FP domain also has the potential to bind two protein partners simultaneously using the alpha-helical and beta-sheet surfaces. The results of this structural study provide critical insights into how Fbxo7 may dimerize (or multimerize) and interact with other regulatory proteins via the FP domain.
| + | |
| - | | + | |
| - | Structure of the FP domain of Fbxo7 reveals a novel mode of protein-protein interaction.,Shang J, Wang G, Yang Y, Huang X, Du Z Acta Crystallogr D Biol Crystallogr. 2014 Jan;70(Pt 1):155-64. doi:, 10.1107/S1399004713025820. Epub 2013 Dec 31. PMID:24419388<ref>PMID:24419388</ref>
| + | |
| - | | + | |
| - | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
| + | |
| - | </div>
| + | |
| - | <div class="pdbe-citations 4l9c" style="background-color:#fffaf0;"></div>
| + | |
| | == References == | | == References == |
| | <references/> | | <references/> |
| | __TOC__ | | __TOC__ |
| | </StructureSection> | | </StructureSection> |
| - | [[Category: Human]] | + | [[Category: Homo sapiens]] |
| - | [[Category: Du, Z]] | + | [[Category: Large Structures]] |
| - | [[Category: Huang, X]] | + | [[Category: Du Z]] |
| - | [[Category: Shang, J]] | + | [[Category: Huang X]] |
| - | [[Category: Wang, G]] | + | [[Category: Shang J]] |
| - | [[Category: Yang, Y]] | + | [[Category: Wang G]] |
| - | [[Category: Alpha/beta fold]]
| + | [[Category: Yang Y]] |
| - | [[Category: Protein binding]]
| + | |
